GeneDx Holdings Statistics

Total Valuation

GeneDx Holdings has a market cap or net worth of $2.07 billion. The enterprise value is $2.07 billion.

Market Cap	2.07B
Enterprise Value	2.07B

Important Dates

The next estimated earnings date is Tuesday, July 28, 2026, before market open.

Earnings Date	Jul 28, 2026
Ex-Dividend Date	n/a

Share Statistics

GeneDx Holdings has 29.69 million shares outstanding. The number of shares has increased by 5.57% in one year.

Current Share Class	29.69M
Shares Outstanding	29.69M
Shares Change (YoY)	+5.57%
Shares Change (QoQ)	+0.98%
Owned by Insiders (%)	2.94%
Owned by Institutions (%)	91.80%
Float	18.60M

Valuation Ratios

PE Ratio	n/a
Forward PE	168.57
PS Ratio	4.68
Forward PS	4.12
PB Ratio	8.15
P/TBV Ratio	19.28
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	4.68
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.09, with a Debt / Equity ratio of 0.66.

Current Ratio	3.09
Quick Ratio	2.83
Debt / Equity	0.66
Debt / EBITDA	364.84
Debt / FCF	n/a
Interest Coverage	-12.73

Financial Efficiency

Return on equity (ROE) is -30.42% and return on invested capital (ROIC) is -13.28%.

Return on Equity (ROE)	-30.42%
Return on Assets (ROA)	-4.37%
Return on Invested Capital (ROIC)	-13.28%
Return on Capital Employed (ROCE)	-7.96%
Weighted Average Cost of Capital (WACC)	14.04%
Revenue Per Employee	$340,522
Profits Per Employee	-$59,852
Employee Count	1,300
Asset Turnover	0.93
Inventory Turnover	10.82

Taxes

In the past 12 months, GeneDx Holdings has paid $334,000 in taxes.

Income Tax	334,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -21.49% in the last 52 weeks. The beta is 1.97, so GeneDx Holdings's price volatility has been higher than the market average.

Beta (5Y)	1.97
52-Week Price Change	-21.49%
50-Day Moving Average	54.80
200-Day Moving Average	97.77
Relative Strength Index (RSI)	67.12
Average Volume (20 Days)	1,172,949

Short Selling Information

The latest short interest is 4.57 million, so 15.40% of the outstanding shares have been sold short.

Short Interest	4.57M
Short Previous Month	4.93M
Short % of Shares Out	15.40%
Short % of Float	24.58%
Short Ratio (days to cover)	4.58

Income Statement

In the last 12 months, GeneDx Holdings had revenue of $442.68 million and -$77.81 million in losses. Loss per share was -$2.69.

Revenue	442.68M
Gross Profit	307.91M
Operating Income	-33.31M
Pretax Income	-77.47M
Net Income	-77.81M
EBITDA	-7.85M
EBIT	-33.31M
Loss Per Share	-$2.69

Full Income Statement

Balance Sheet

The company has $170.69 million in cash and $168.19 million in debt, giving a net cash position of $2.49 million or $0.08 per share.

Cash & Cash Equivalents	170.69M
Total Debt	168.19M
Net Cash	2.49M
Net Cash Per Share	$0.08
Equity (Book Value)	254.12M
Book Value Per Share	8.57
Working Capital	182.99M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$9.31 million and capital expenditures -$19.34 million, giving a free cash flow of -$28.65 million.

Operating Cash Flow	-9.31M
Capital Expenditures	-19.34M
Depreciation & Amortization	25.46M
Net Borrowing	21.41M
Free Cash Flow	-28.65M
FCF Per Share	-$0.97

Full Cash Flow Statement

Margins

Gross margin is 69.56%, with operating and profit margins of -7.52% and -17.58%.

Gross Margin	69.56%
Operating Margin	-7.52%
Pretax Margin	-17.50%
Profit Margin	-17.58%
EBITDA Margin	-1.77%
EBIT Margin	-7.52%
FCF Margin	n/a

Dividends & Yields

GeneDx Holdings does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-5.57%
Shareholder Yield	-5.57%
Earnings Yield	-3.75%
FCF Yield	-1.38%

Analyst Forecast

The average price target for GeneDx Holdings is $78.44, which is 12.35% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$78.44
Price Target Difference	12.35%
Analyst Consensus	Strong Buy
Analyst Count	9
Revenue Growth Forecast (3Y)	19.70%
EPS Growth Forecast (3Y)	9.54%

Stock Forecasts

Stock Splits

The last stock split was on May 4, 2023. It was a reverse split with a ratio of 1:33.

Last Split Date	May 4, 2023
Split Type	Reverse
Split Ratio	1:33

Scores

GeneDx Holdings has an Altman Z-Score of 4.26 and a Piotroski F-Score of 3.

Altman Z-Score	4.26
Piotroski F-Score	3